Form 4 for ALLO Allogene Therapeutics, Inc.
Accepted 2023-04-26 00:00:00 ET · period of report 2023-04-24 · accession 0001593968-23-000643 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-04-26 | 2023-04-24 | ALLO | MOORE TIMOTHY L. | Chief Technical Off | A - Grant | $0.00 | +186.2K | 186.2K | New | $0 |
| D | 2023-04-26 | 2023-04-24 | ALLO | MOORE TIMOTHY L. | Chief Technical Off | A - Grant | $0.00 | +831.0K | 831.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-04-24 | A | A | 186,219 | $0.00 | 186,219 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2023-04-24 | A | A | 831,024 | $0.00 | 831,024 | D | $5.37 · — to 2033-04-24 | 831,024 Common Stock | (F1) 25% of the shares subject to the stock option shall vest on April 24, 2024, and the remaining shares shall vest in 36 equal monthly installments thereafter. |